Membrane-camouflaged liposomes co-delivering L-Arg and NMN in macrophage NO metabolism: an in vitro study
In in vitro experiments, macrophage membrane-camouflaged liposomes carrying NMN and L-Arg raised intracellular NO while lowering NQO1, cleared ROS, shifted macrophages toward an anti-inflammatory M2 phenotype and reduced ox-LDL uptake and foam cell formation. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract describes an iNOS-mediated pathological NO burst in plaque macrophages as a key driver of inflammation and oxidative stress in atherosclerosis. [1]
In vitro, M-AN@Lip increased intracellular NO while significantly downregulating NQO1, which the authors interpret as reprogramming NO metabolism toward a protective pathway. [1]
M-AN@Lip significantly inhibited ox-LDL uptake and foam cell formation by downregulating CD36, MSR1 and SRB1, and the authors propose this as a promising nanotherapeutic strategy. [1]
The source at a glance
- Study type / format
- In vitro experimental study (abstract)
- Population / context
- Plaque macrophages studied in vitro, using a liposome formulation carrying NMN and L-Arg
- Summary based on
- Study abstract
- Original publication
- August 12, 2026
Atherosclerotic plaque macrophages and pathological NO burst
The abstract links atherosclerosis progression to metabolic dysfunction of plaque macrophages. There, a pathological burst of nitric oxide (NO) driven by the enzyme inducible nitric oxide synthase (iNOS) is described as a key driver of inflammation and oxidative stress. Against this background, the authors designed liposomes coated with macrophage membranes (M-AN@Lip) to deliver nicotinamide mononucleotide (NMN) and L-arginine (L-Arg) together, aiming to regulate macrophage NO metabolic homeostasis precisely.
Supporting source [1]
In vitro: higher NO, lower NQO1, M2 shift, less foam cell formation
In vitro experiments showed that M-AN@Lip effectively increased intracellular NO generation while significantly downregulating expression of the oxidative stress-related enzyme NAD(P)H quinone oxidoreductase 1 (NQO1). The authors interpret this as reprogramming macrophage NO metabolism away from a pathological iNOS-dominated pathway toward a protective one. This shift was accompanied by clearance of intracellular reactive oxygen species (ROS), enhancement of the endogenous antioxidant enzyme system and polarization of macrophages toward an anti-inflammatory M2 phenotype. M-AN@Lip also significantly inhibited oxidized low-density lipoprotein (ox-LDL) uptake and foam cell formation by downregulating the scavenger receptors CD36, MSR1 and SRB1.
Supporting source [1]
Abstract-only scope: proposed nanotherapeutic strategy, not proven therapy
The abstract concludes that this biomimetic nano-system can achieve combined anti-inflammatory, antioxidant and anti-foam-cell effects through synergistic regulation of NO metabolism, and calls it a promising novel nanotherapeutic strategy for atherosclerosis. These are in vitro findings and a proposal; the abstract reports no animal or human study, no clinical outcomes and no dosing. The full text was not reviewed, so details of design, sample sizes and statistics remain unknown.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. All reported effects are in vitro; no animal or human data, clinical outcomes or dosing are reported. The nanotherapeutic strategy is proposed, not validated.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Li X, Yuan Y, Lian C, Zhu D, Wang Y, Jia Z. · europepmc.org · August 12, 2026